10x Genomics stock hits 52-week high at 66.95 USD

10x Genomics Inc. (TXG) stock has reached a noteworthy accomplishment by attaining a 52-week high of 66.95 USD. This accomplishment is accompanied by a market capitalization of $8.71 billion. However, InvestingPro analysis indicates that the stock is possibly overvalued compared to its Fair Value, positioning it among companies on the Most Overvalued list.

This rise in the stock's value is evidence of a substantial growth trajectory over the past year. The 1-year total return for the stock has been an impressive 385.93%, demonstrating the strong investor confidence and potential for further expansion. The recent momentum has been truly remarkable, with a year-to-date return of 302% and a six-month increase of 213.73%.

InvestingPro Tips suggest that the stock displays considerable price fluctuations, evidenced by a beta of 2.08. Investors interested in further understanding can obtain TXG's extensive Pro Research Report, one of 1,400+ available on InvestingPro, along with 13 additional ProTips. The increase in stock price is indicative of the company's dominant market standing and the favorable response to its innovative genomic solutions.

In additional news, 10X Genomics disclosed its second-quarter results for 2026, surpassing Wall Street's projections. The company reported a revenue of $151.04 million, outpacing the estimated $146.64 million, and an adjusted loss per share of $0.14, which is an improvement over the anticipated $0.24 loss. While these financial results were positive, the company's outlook was somewhat subdued due to its shift towards the new Atera platform.

Stifel maintained a Buy rating on 10X Genomics, pointing to the upcoming commercialization of the Atera instrument and enhancements in spatial biology software. Conversely, RBC Capital initiated coverage with a Sector Perform rating, acknowledging the potential for growth in Atera launch but expressing concerns about the maturity of their single-cell franchise.

These updates indicate a blend of hope and caution among analysts concerning the company's future outlook.